PDAC Weighs Risks, Benefits of Implantable Buprenorphine

Safety concerns were front and center at Thursday's meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) reviewing Titan Pharmaceuticals Inc.'s application for Probuphine, an implantable device delivering a steady dose of buprenorphine for up to six months for opioid dependence.